Original Study| Volume 23, ISSUE 2, P155-161, February 2023

Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience

Published:November 22, 2022DOI:



      RNA-based genomic risk assessment estimates chemotherapy benefit in patients with hormone-receptor positive (HR+)/Human Epidermal Growth Factor 2-negative (ERBB2-) breast cancer (BC). It is virtually used in all patients with early HR+/ERBB2- BC regardless of clinical recurrence risk.

      Patients and methods

      We conducted a retrospective chart review of adult patients with early-stage (T1-3; N0; M0) HR+/ERBB2- BC who underwent genomic testing using the Oncotype DX (Exact Sciences) 21-genes assay. Clinicopathologic features were collected to assess the clinical recurrence risk, in terms of clinical risk score (CRS) and using a composite risk score of distant recurrence Regan Risk Score (RRS). CRS and RRS were compared to the genomic risk of recurrence (GRS).


      Between January 2015 and December 2020, 517 patients with early-stage disease underwent genomic testing, and clinical data was available for 501 of them. There was statistically significant concordance between the 3 prognostication methods (P < 0.01). Within patients with low CRS (n = 349), 9.17% had a high GRS, compared to 8.93% in patients with low RRS (n = 280). In patients with grade 1 histology (n = 130), 3.85% had a high GRS and 68.46% had tumors > 1 cm, of whom only 4.49% had a high GRS. Tumor size > 1cm did not associate with a high GRS.


      Genomic testing for patients with grade 1 tumors may be safely omitted, irrespective of size. Our finds call for a better understanding of the need for routine genomic testing in patients with low grade/low clinical risk of recurrence.



      BC: (Breast ancer), HR: (Hormone Receptor), ERBB2: (Human epidermal growth factor receptor 2), GRS: (Genomic Risk Score), CRS: (Clinical Risk Score), RRS: (Regan Risk Score), ER: (Estrogen Receptor), PR: (Progesterone Receptor), QALY (Quality-Adjusted Life Year)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bray F
        • Ferlay J
        • Soerjomataram I
        • Siegel RL
        • Torre LA
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA: A Cancer J Clinicians. 2018; 68: 394-424
      1. National Cancer Institute. Surveillance, epidemiology, and end results program. Access date: June 29, 2022.

        • Howlader N
        • Altekruse SF
        • Li CI
        • et al.
        US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 Status.
        JNCI: J National Cancer Institute. 2014; 106
        • Chavez-MacGregor M
        • Mittendorf EA
        • Clarke CA
        • Lichtensztajn DY
        • Hunt KK
        • Giordano SH.
        Incorporating tumor characteristics to the American Joint Committee on cancer breast cancer staging system.
        The Oncol. 2017; 22: 1292-1300
        • Pan H
        • Gray R
        • Braybrooke J
        • et al.
        20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.
        N Engl J Med. 2017; 377: 1836-1846
        • Sparano JA
        • Gray RJ
        • Makower DF
        • et al.
        Prospective validation of a 21-gene expression assay in breast cancer.
        N Engl J Med. 2015; 373: 2005-2014
        • Gluz O
        • Nitz UA
        • Christgen M
        • et al.
        West german study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment.
        JCO. 2016; 34: 2341-2349
        • Harris LN
        • Ismaila N
        • McShane LM
        • et al.
        Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
        JCO. 2016; 34: 1134-1150
        • Krop I
        • Ismaila N
        • Andre F
        • et al.
        Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline focused update.
        JCO. 2017; 35: 2838-2847
        • Paik S
        • Kim C
        • Baehner FL
        • Park T
        • Wickerham DL
        • Wolmark N.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        The New England J Med. 2004; (Published online): 10
        • Sparano JA
        • Gray RJ
        • Makower DF
        • et al.
        Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.
        N Engl J Med. 2018; 379: 111-121
        • Batra A
        • Patel A
        • Gupta VG
        • et al.
        Oncotype DX: Where Does It Stand in India?.
        JGO. 2019; : 1-2
        • Ozmen V
        • Cakar B
        Division of medical oncology, department of internal medicine, ege university school of medicine, Izmir, Turkey, et al. cost effectiveness of gene expression profiling in patients with early-stage breast cancer in a middle-income country, Turkey: results of a prospective multicenter study.
        Eur J Breast Health. 2019; 15: 183-190
        • Fatima C.
        70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
        N Engl J Med. 2016; (Published online): 13
        • Pagani O
        • Francis PA
        • Fleming GF
        • et al.
        Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT.
        J Clin Oncol. 2019; 38: 28
        • Pagani O
        • Láng I
        • Ciruelos E
        • et al.
        Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer.
        N Engl J Med. 2014; (Published online): 12
        • Francis PA
        • Láng I
        • Climent MA
        • et al.
        Adjuvant Ovarian Suppression in Premenopausal Breast Cancer.
        N Engl J Med. 2015; (Published online): 11
        • Viale G
        • Regan MM
        • Dell'Orto P
        • et al.
        Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
        Ann Oncol. 2011; 22: 2201-2207
        • Ademuyiwa FO
        • Miller A
        • O'Connor T
        • et al.
        The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
        Breast Cancer Res Treat. 2011; 126: 797-802
        • Sparano JA
        • Gray RJ
        • Ravdin PM
        • et al.
        Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
        N Engl J Med. 2019; (Published online): 11
        • Orucevic A
        • Bell JL
        • King M
        • McNabb AP
        • Heidel RE.
        Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
        The Breast. 2019; 46: 116-125
        • Orucevic A
        • Bell JL
        • McNabb AP
        • Heidel RE.
        Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
        Breast Cancer Res Treat. 2017; 163: 51-61
        • Singh K
        • He X
        • Kalife ET
        • Ehdaivand S
        • Wang Y
        • Sung CJ.
        Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
        Breast Cancer Res Treat. 2018; 168: 29-34
        • Hornberger J
        • Cosler LE
        • Lyman GH.
        Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
        Am J Manag Care. 2005; 11: 313-324
        • Oestreicher N
        • Ramsey SD
        • McCune JS
        • Linden HM
        • Veenstra DL.
        The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
        Cancer. 2005; 104: 2054-2062
        • Lyman GH
        • Cosler LE
        • Kuderer NM
        • Hornberger J.
        Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
        Cancer. 2007; 109: 1011-1018